Optimizing Insulin Use in Type 2 Diabetes: Role of Basal and Prandial Insulin in Long-Term Care Facilities
To access this article, please choose from the options below
I have served on a diabetes advisory board for sanofi-aventis U.S. from 2004 to the present and hold stock in Amylin Pharmaceuticals. I have no other financial interest in any product discussed in the manuscript.
Editorial support has been provided by sanofi-aventis U.S.
PII: S1525-8610(07)00353-2
doi:10.1016/j.jamda.2007.08.002
© 2007 American Medical Directors Association. Published by Elsevier Inc. All rights reserved.
